Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. J Surg Oncol 2021 May;123(6):1405-1413

Date

04/09/2021

Pubmed ID

33831252

DOI

10.1002/jso.26395

Scopus ID

2-s2.0-85103999698 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

Treatment of localized pancreatic cancer has also evolved to prioritize preoperative (neoadjuvant) multimodality therapy over a surgery-first approach. Given the complexities of pancreatic cancer staging and the challenge of delivering multiple treatment modalities (chemotherapy, radiation therapy, and surgery), an experienced and highly integrated multidisciplinary team is necessary to achieve the best outcomes. In this review, we will discuss our institutional experience with neoadjuvant therapy, guiding principles for treatment, and outline the landscape for future investigations.

Author List

Ward EP, Evans DB, Tsai S

Author

Douglas B. Evans MD Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Fluorouracil
Humans
Leucovorin
Neoadjuvant Therapy
Pancreatic Neoplasms
Randomized Controlled Trials as Topic